The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation
Alexa S. Green(Délégation Paris 5), Jérôme Tamburini(Centre National de la Recherche Scientifique), Patrick Mayeux(Université Paris Cité), Mireille Lambert(Inserm), Sophie Park(Centre Hospitalier Universitaire de Grenoble), Norbert Ifrah(Institut National du Cancer), Marc Foretz(Centre National de la Recherche Scientifique), Olivier Boyer(Inserm), Benoı̂t Viollet(Centre National de la Recherche Scientifique), Thiago Trovati Maciel(Inserm), Nicolas Chapuis(Délégation Paris 5), Christophe Arnoult(Centre Hospitalier Universitaire de Rouen), Olivier Hermine(Centre National de la Recherche Scientifique), Didier Bouscary(Université Paris Cité), Valérie Bardet(Délégation Paris 5), Ivan Cruz Moura(Inserm), Catherine Lacombe(Centre National de la Recherche Scientifique), François Dreyfus(Université Paris-Sud), Lise Willems(Hôpital Cochin)
Cited by 196
Related Papers
Metformin: From Mechanisms of Action to Therapies
|Cell Metabolism|2014|1.5k
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
|New England Journal of Medicine|2002|1.2k
Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state
|Journal of Clinical Investigation|2010|1.2k
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2017|736
Metformin: update on mechanisms of action and repurposing potential
|Nature Reviews Endocrinology|2023|621